Published in Onco Targets Ther on May 22, 2017
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Inflammation and cancer. Nature (2002) 53.78
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med (2006) 26.37
7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol (2010) 5.64
The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol (2013) 4.09
A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer (2011) 3.59
Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol (2011) 2.89
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer (2011) 2.88
Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol (2005) 2.76
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res (2010) 2.50
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer (2012) 2.41
Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A (2007) 2.27
Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer (2011) 2.18
Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol (2012) 1.84
Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer (2012) 1.82
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer (2013) 1.77
Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer (2013) 1.67
A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol (2013) 1.60
Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol (2014) 1.27
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS One (2013) 1.23
Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol (2011) 1.22
Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery (2006) 1.20
VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine (2005) 1.16
Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol (2014) 1.10
A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer. Onco Targets Ther (2015) 1.00
Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy. World J Surg Oncol (2013) 0.99
The effects of hematological parameters and tumor-infiltrating lymphocytes on prognosis in patients with gastric cancer. Cancer Biomark (2013) 0.88
The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Med Oncol (2013) 0.87